부산대학교 도서관

Nelson BE; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA.; Naing A; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA.; Fu S; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA.; Sheth RA; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, USA.; Murthy R; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, USA.; Piha-Paul S; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA.

Publisher: Elsevier Ltd Country of Publication: England NLM ID: 9918281581106676 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-0188 (Electronic) Linking ISSN: 25900188 NLM ISO Abbreviation: Immunooncol Technol Subsets: PubMed not MEDLINE

Sakellaropoulos, T; Vougas, K; Narang, S; Koinis, F; Kotsinas, A; Polyzos, A; Moss, TJ; Piha-Paul, S; Zhou, H; Kardala, E

CELL REPORTS. 29(11):3367

Fu S; Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA.; Hirte H; Juravinski Cancer Centre, Hamilton, ON, Canada.; Welch S; London Health Sciences Centre, London, ON, Canada.; Ilenchuk TT; Soricimed Biopharma Inc., Moncton, NB, Canada.; Lutes T; Soricimed Biopharma Inc., Moncton, NB, Canada.; Rice C; Soricimed Biopharma Inc., Moncton, NB, Canada.; Fields N; Sagecon Inc., Oakville, ON, Canada.; Nemet A; CLINSIG Research Consulting Inc., Brampton, ON, Canada.; Dugourd D; Soricimed Biopharma Inc., Moncton, NB, Canada.; Piha-Paul S; Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA.; Subbiah V; Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA.; Liu L; Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA.; Gong J; Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA.; Hong D; Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA.; Stewart JM; Soricimed Biopharma Inc., Moncton, NB, Canada. jstewart@soricimed.com.

Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

Fu S; Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA.; Hirte H; Juravinski Cancer Centre, Hamilton, ON, Canada.; Welch S; London Health Sciences Centre, London, ON, Canada.; Ilenchuk TT; Soricimed Biopharma Inc., Moncton, NB, Canada.; Lutes T; Soricimed Biopharma Inc., Moncton, NB, Canada.; Rice C; Soricimed Biopharma Inc., Moncton, NB, Canada.; Fields N; Sagecon Inc., Oakville, ON, Canada.; Nemet A; CLINSIG Research Consulting Inc., Brampton, ON, Canada.; Dugourd D; Soricimed Biopharma Inc., Moncton, NB, Canada.; Piha-Paul S; Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA.; Subbiah V; Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA.; Liu L; Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA.; Gong J; Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA.; Hong D; Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA.; Stewart JM; Soricimed Biopharma Inc., Moncton, NB, Canada. jstewart@soricimed.com.

Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: PubMed not MEDLINE

Henary, H; George, G C; Wheler, J; Naing, A; Piha-Paul, S; Fu, S; Mistry, R; Zinner, R; Kurzrock, R; Hong, D S

Cancer Chemotherapy & Pharmacology (CANCER CHEMOTHER PHARMACOL), Sep2015; 76(3): 597-603. (7p)

Dumbrava EI; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Brusco L; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Daniels M; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Program of Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Wathoo C; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Shaw K; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Lu K; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Program of Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Zheng X; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Strong L; Program of Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Litton J; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Arun B; Program of Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Eterovic AK; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Routbort M; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Patel K; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Qi Y; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Piha-Paul S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Subbiah V; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Hong D; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Kopetz S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Mendelsohn J; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Mills GB; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Chen K; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2473-4284 (Print) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: PubMed not MEDLINE

Fu S; Departments of Investigational Cancer Therapeutics. Electronic address: siqingfu@mdanderson.org.; Hou MM; Departments of Investigational Cancer Therapeutics; Division of Hematology-Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.; Naing A; Departments of Investigational Cancer Therapeutics.; Janku F; Departments of Investigational Cancer Therapeutics.; Hess K; Biostatistics.; Zinner R; Departments of Investigational Cancer Therapeutics.; Subbiah V; Departments of Investigational Cancer Therapeutics.; Hong D; Departments of Investigational Cancer Therapeutics.; Wheler J; Departments of Investigational Cancer Therapeutics.; Piha-Paul S; Departments of Investigational Cancer Therapeutics.; Tsimberidou A; Departments of Investigational Cancer Therapeutics.; Karp D; Departments of Investigational Cancer Therapeutics.; Araujo D; Sarcoma.; Kee B; GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.; Hwu P; Sarcoma.; Wolff R; GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.; Kurzrock R; University of California San Diego, Moores Cancer Center, La Jolla, USA.; Meric-Bernstam F; Departments of Investigational Cancer Therapeutics.

Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

Said R; Department of Investigational Cancer Therapeutics.; Banchs J; Wheler J; Hess KR; Falchook G; Fu S; Naing A; Hong D; Piha-Paul S; Ye Y; Yeh E; Wolff RA; Tsimberidou AM

Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

Veasey Rodrigues H; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: hveasey@gmail.com.; Baracos VE; Wheler JJ; Parsons HA; Hong DS; Naing A; Fu S; Falchoock G; Tsimberidou AM; Piha-Paul S; Chisholm G; Kurzrock R

Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

Henary H; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA.; Hong DS; Falchook GS; Tsimberidou A; George GC; Wen S; Wheler J; Fu S; Naing A; Piha-Paul S; Janku F; Kim KB; Hwu P; Kurzrock R

Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE